# Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

> **NCT02197806** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 65 (actual)

## Conditions studied

- Presbyopia

## Interventions

- **DRUG:** AGN-199201
- **DRUG:** AGN-190584
- **DRUG:** AGN-199201 Vehicle

## Key facts

- **NCT ID:** NCT02197806
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2014-10
- **Final completion:** 2014-11
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02197806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02197806, "Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02197806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*